Search for a clinical study
A Multicenter, Open-Label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 ...
This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 ...
Cleopattra: Effects of Nnc6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants with Transthyretin Amyloid Cardiomyopathy
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy ...
Alnylam ALN-APP-001: Phase I, Placebo-Controlled Trial of ALN-APP in Participants with Early-Onset Alzheimer’S Disease
Who is Eligible Ages 18+ Must have had symptoms of Alzheimer’s disease prior to age 65 Diagnosis of Alzheimer’s disease Must be able to complete MRI Must be able to tolerate lumbar puncture No history of ...
Sc2i-Woundx-001-Woundx Pilot Trial: Proof of Concept Feasibility for the Clinical Operations of Woundx in Aiding Clinicians Identify Wounds That Are Ready for Surgical Closure
The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and ...
A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Rls-0071 in Newborns with Moderate ...
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left ...
Efficacy and Safety of Nnc0487-0111 Compared to Placebo on Morbidity and Mortality in People with Heart Failure with Preserved or Mildly Reduced Ejection Fraction ...
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced ...
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Dyne-101 Administered to Participants with Myotonic Dystrophy Type 1 ...
This Phase 3 study was designed based on the results of ACHIEVE. It is a randomized,double-blind study with a 48-week Placebo-Controlled Period to assess the efficacy, safety,and tolerability of DYNE-101 ...
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Obesity prevalence in persons with T1D has increased, which further complicates managementd risk for complications. The proposed study is relevant to public health because it helps us understand the role ...
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants with Isocitrate Dehydrogenase 1 (Idh1)-Mutant Glioma
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant ...
A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and ...
A Phase 1b/2 trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, ...